Lincoject S®

Lincomycin + Spectinomycin

لینکوجکت اس | Lincoject S
  • - animals:
  • - Packaging:
  • 50 & 100 ml vials

Product properties


Each ml contains:

Lincomycin HCL 50 mg
Spectinomycin sulfate 100 mg

Lincomycin is produced by Streptomyces lincolensis and is readily soluble in water.

Spectinomycin is produced by Streptomyces spectabilis which, is slightly alkaline and soluble in water.

Mechanism of Action:

Lincomycin belongs to group of lincosamide antibiotics with bacteriostatic properties. It binds to 50s unit of bacterial ribosome and inhibits protein synthesis. Place of binding of this antibiotic to bacterial ribosome is near to binding place of chloramphenicol and erythromycin. Possibly some parts of these sites are common for these antibiotics that can explain the antagonism between lincomycin and erythromycin. It also can be the reason of resistance to lincomycin due to lack of its ability to attach to bacterial ribosomes. Spectinomycin belongs to Aminocyclitol group of antibiotics which inhibits protein synthesis by binding to 30s unit on bacterial ribosome’s. Laboratory tests have proved that simultaneous use of these antibiotics has better effect than using them separately against mycoplasma and bacterial species. The peak of serum level for Lincomycin is achieved 4-6 hours after injection. It is widely distributed in body and its concentration in most tissues such as bones reaches to a suitable level. The highest concentration is achieved in kidneys and liver. The lowest concentration is detectable in cerebrospinal fluid (CSF).Lincomycin is metabolized in the liver and excreted via bile (Faeces) and urine. Spectinomycin is well absorbed after injection and reaches its maximum plasma concentration within one hour. It does not enter eyes and CSF and its molecular ability for protein binding is low. It excreted into urine via glomerular infiltration without any change.

Indications of use

Lincomycin + spectinomycin injectable solution is used against  infections due to organisms susceptible to lincomycin and / or spectinomycin (including Gram positive bacteria like Staphylococci, beta-haemolytic Streptococci, Mycoplasma species and some Gram negative bacteria) in suckling calves, sheep and goats.

Sheep and goats: Primary and secondary infections of respiratory tract due to mycoplasma and organisms susceptible to lincomycin and spectinomycin, pneumonia, infectious

pleuropneumonia, foot rot due to bactericides nodosus and agalactia.

Suckling calves (before start of rumination): Treatment of respiratory / digestive infections (pneumo-enteritis) due to organisms susceptible to this drug.

Dosage and route of administration

Sheep and goats: 1 ml for 10 kg bodyweight by intramuscular injection once a day

for 3 consecutive days.

Suckling calves: 1 ml for 10kg bodyweight by intramuscular injection twice in first day and once a day for 2-4 consecutive days.

Withdrawal Time

Meat :14 days

Milk :48 hours

Drug interactions:

Lincomycin is not compatible with novobiocin and kanamycin sulfate. Lincomycin precipitates if it is used simultaneously with benzyl penicillin and phenytoin.

Macrolides and chloramphenicol have antagonism effect with lincosamides and should not be used simultaneously.


Do not use in animals hypersensitive to this product.

Use of this drug in solipeds may causes colitis.

Use of this drug in non-target animals may causes digestive complications.

In some cases it may causes transient diarrhea in sheep / goats.

Sometimes reduction of appetite and milk quantity is reported in goats after injection. In very rare cases, abortion or death of treated pregnant sheep has been reported during third period of pregnancy.

Storage conditions

Keep away from direct light and below 25º C.